News

The Alzheimer’s Drug Discovery Foundation and Pfizer’s Centers for Therapeutic Innovation are  supporting a Johns Hopkins University School of Medicine effort to develop therapies for Alzheimer’s, Parkinson’s, and other neurodegenerative diseases. Valina Dawson, a neurology professor who is co-director of neuroregeneration and stem cell programs at Johns Hopkins’ Institute for Cell Engineering, will…

Menopause triggers numerous changes in a woman’s body — and, apparently, metabolic changes in the brain as well that puts middle-age women at greater risk of Alzheimer’s disease, a study reports. This finding provides new insights into why women have a higher incidence of this neurological disease, even when a…

The Alzheimer’s disease community has grown accustomed to news of an endless string of failures in clinical trials of potential treatments. In fact, only four such treatments went on to win approval between 1998 and 2014 — addressing symptoms but not altering the relentless course of the disease. PhRMA…

A list of more than 80 compounds in clinical trials for Alzheimer’s disease, released by PhRMA, inevitably brings to mind all those that failed previously. But researchers view the new list as a source of hope, increasingly confident a breakthrough may be among them. Alzheimer’s News Today spoke…

A new test developed by researchers at UC San Francisco and UC San Diego can better predict which cognitively normal adults will develop Alzheimer’s dementia later in life than testing for the well-known genetic variant APOE E4 alone, according to a new study. The study, titled “Polygenic…

The Ontario Neurodegenerative Disease Research Initiative (ONDRI) was designed by Ontario neuroscientists to improve early diagnosis and treatment of neurodegenerative diseases that are inflicted with dementia, such as Alzheimer’s disease. The specifics of this initiative are detailed in an article titled “The Ontario Neurodegenerative Disease Research Initiative (ONDRI),” published…

Investigators at University of North Texas Health Science Center (UNTHSC) in Fort Worth want to understand why people of Hispanic descent develop cognitive loss and Alzheimer’s disease earlier than non-Hispanics. Their new study, funded by a $12 million grant from the National Institutes of Health, aims to add knowledge…

Acadia Pharmaceuticals is starting its Phase 3 HARMONY trial to evaluate Nuplazid (pimavanserin) as a treatment for hallucinations and delusions associated with dementia-related psychosis. Currently, there is no approved therapy for this condition. Acadia’s announcement comes in the wake of the U.S. Food and Drug Administration designating Nuplazid a Breakthrough…

In a discovery that might provide an entirely new angle to Alzheimer’s disease research, scientists have mapped lymphatic vessels to the outside of the brains of living humans. Because these vessels are the main route traveled by immune cells, the finding, described in the journal eLife, may allow scientists…

UsAgainstAlzheimer’s released a report showing that Alzheimer’s disease is both an urgent healthcare concern among older U.S. military veterans and a threat to the future of younger ones. Titled “Veterans and Alzheimer’s: Meeting the Crisis Head On,” the report highlights the unique risk factors veterans facee, including…